Changes in treatment of hyperglycemia in a hypertensive type 2 diabetes population as renal function declines
暂无分享,去创建一个
[1] Andrea Cherrington,et al. Standards of Medical Care in Diabetes—2017 Abridged for Primary Care Providers , 2017, Clinical Diabetes.
[2] L. Weinrauch,et al. Renal Function Alters Antihypertensive Regimens in Type 2 Diabetic Patients , 2016, Journal of clinical hypertension.
[3] Akshay S. Desai,et al. Strategies for glucose control in a study population with diabetes, renal disease and anemia (Treat study). , 2016, Diabetes research and clinical practice.
[4] Ananda Sen,et al. Phosphate binder pill burden, patient‐reported non‐adherence, and mineral bone disorder markers: Findings from the DOPPS , 2016, Hemodialysis international. International Symposium on Home Hemodialysis.
[5] D. Tarng,et al. Metformin use and mortality in patients with advanced chronic kidney disease: national, retrospective, observational, cohort study. , 2015, The lancet. Diabetes & endocrinology.
[6] Sei J. Lee,et al. Potential overtreatment of diabetes mellitus in older adults with tight glycemic control. , 2015, JAMA internal medicine.
[7] D. Matthews,et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes , 2015, Diabetologia.
[8] Silvio E. Inzucchi,et al. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. , 2014, JAMA.
[9] D. Matthews,et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes , 2014, Diabetes Care.
[10] Deepak L. Bhatt,et al. Do dipeptidyl peptidase-4 inhibitors increase the risk of heart failure? , 2014, JACC. Heart failure.
[11] Daniala L. Weir,et al. Sitagliptin use in patients with diabetes and heart failure: a population-based retrospective cohort study. , 2014, JACC. Heart failure.
[12] B. Zinman,et al. Liraglutide Promotes Natriuresis but Does Not Increase Circulating Levels of Atrial Natriuretic Peptide in Hypertensive Subjects With Type 2 Diabetes , 2014, Diabetes Care.
[13] M. Woodward,et al. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. , 2014, The New England journal of medicine.
[14] W. van Biesen,et al. Glucose-lowering drugs in patients with chronic kidney disease: a narrative review on pharmacokinetic properties. , 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[15] J. McGill,et al. American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary. , 2013, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[16] J. McGill,et al. American Association of Clinical Endocrinologists’ Comprehensive Diabetes Management Algorithm 2013 Consensus Statement , 2013, Endocrine Practice.
[17] Kuo-Chin Huang,et al. Consensus Statement , 2012, Asia-Pacific journal of public health.
[18] B. Davis,et al. Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2001, Diabetes care.
[19] John S Yudkin,et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study , 2000, BMJ : British Medical Journal.
[20] A. Levey,et al. A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.
[21] R. Holman,et al. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.